Fig. 5From: Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patientsThe acceptability of IDegLira based on QALE compared with degludec based on DUAL II China. QALE ,quality-adjusted life expectancyBack to article page